Nine-Valent HPV Vaccine Protects Against Additional Oncogenic HPV Types

Both the quadrivalent and bivalent human papillomavirus (HPV) vaccines protect against HPV 16 and 18 (which account for about 70% of cervical cancers). To test whether a 9-valent product would extend this protection to HPV 31, 33, 45, 52, and 58, investigators conducted a manufacturer-supported trial in which 14,209 women (age range, 16–26) were randomized to receive the quadrivalent HPV vaccine or the 9-valent product.

In per-protocol analyses limited to women who were HPV-negative at study entry, the 9-valent vaccine prevented >96% of high-grade cervical, vaginal, or vulvar neoplasia or cancers related to HPV 31, 33, 45, 52, and 58, while also lowering risk for persistent HPV infection with these types. Antibody titers against HPV 6, 11, 1…